Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin	Chemically-Induced Disorders, Drug-Induced Ototoxicity, Drug-Related Side Effects and Adverse Reactions, Ear Diseases, Neurologic Manifestations, Ototoxicity, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, injury, nervous system disorder, otorhinolaryngologic disease, radiation injury	Recruiting	Phase 2	2026-10-01		NCT05730283

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Johns Hopkins University	579
Kevin Winthrop	2
Mayo Clinic	970
Medical University of South Carolina	262
National Center for Advancing Translational Sciences (NCATS)	127
National Institute on Deafness and Other Communication Disorders (NIDCD)	187
National Jewish Health	31
Northwell Health	107
Oricula Therapeutics	1
The University of Texas Health Science Center at Tyler	3
University of California, San Francisco	637
University of Washington	397

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Johns Hopkins University	Baltimore	United States	25
Mayo Clinic	Rochester	United States	664
Medical University of South Carolina	Charleston	United States	628
National Jewish Health	Denver	United States	72
Northwell Health	Manhasset	United States	34
Oregon Health & Science University	Portland	United States	261
University of California, San Francisco	San Francisco	United States	294
University of Texas Health Science Center	Tyler	United States	2